Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Next Previous
Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obicetrapib (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms BROOKLYN
  • Sponsors NewAmsterdam Pharma

Most Recent Events

  • 10 Jan 2025 According to a NewAmsterdam Pharma media release, data from the study expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25.
  • 10 Jan 2025 According to a NewAmsterdam Pharma media release, company plans to announce additional data from this study throughout 2025.NewAmsterdam expects to report additional data at an upcoming medical conference and to publish the data in a major medical journal.
  • 18 Nov 2024 According to a NewAmsterdam Pharma Media Release, company reported topline data from BROOKLYN in the third quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top